Effectiveness of add‐on therapy with SGLT2 inhibitors or GLP ‐1 receptor agonists in adults with type 1 diabetes: A prospective DPV registry study

BACKGROUND AND AIMSAccording to preliminary study results, individuals with type 1 diabetes and overweight status, insufficient metabolic control, or microvascular or macrovascular complications may benefit from add-on therapy with sodium-glucose co-transporter 2 inhibitors (SGLT2is) or glucagon-like peptide 1 receptor agonists (GLP-1-RAs).[1][2][3] However, although these drugs are successfully used to treat type 2 diabetes, they are currently not authorized for use in the treatment of type 1 diabetes because of safety concerns and are therefore used only off-label in these individuals.4,5 Using real-world data from the Diabetes Prospective Follow-up Registry (DPV), Seufert et al. previously analysed clinical outcomes after 12 months of adjunct SGLT2i treatment in adults with type 1 diabetes.6 Here, we supplement the previous results by analysing changes after a longer study period in an extended study population and additionally investigate the effects of add-on therapy with GLP-1-RAs on clinical outcomes. | METHODSThe data were taken from the real-world Diabetes Prospective Follow-up Registry (DPV) as approved by the ethics committee of the University of Ulm, Germany.7 We included adults with type 1 diabetes who started add-on therapy with SGLT2is or GLP-1-RAs between 2012 and 2023 and maintained it for at least 3 months.The study populations were described using medians (first and third quartiles (q1/q3)) for continuous variables or numbers and percentages for categorical variables.